Male
Multidisciplinary Team(s)
Hematologic (Malignant)
Department/Research Program(s)
Department of Oncology
Cancer Type(s)
Hodgkin's Lymphoma
Leukemia
Lymphoma
Non-Hodgkin's Lymphoma
Contact Info
Email:
ramchanr@karmanos.org
Education
Fellowship
Hematology-Oncology, St. John Health Systems, Providence Hospital
Medical School
Ross University School of Medicine
Residency
Drexel Univeristy College of Medicine - Habnemann University, Philadelphia, PA
Professional Memberships/Associations
American Society of Hematology
American Society of Clinical Oncology
American College of Physicians
Board Certifications
American Board of Internal Medicine
Clinical Interests
Hematology Oncology
Research Interests
Lymphoma and myeloma
Publications
Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) for Patients with Relapsed or Refractory Hodgkin Lymphoma. Authors: Anas Younes, Ajay K Gopal, Scott E. Smith, Stephen M Ansell, Joseph D Rosenblatt, Kerry J Savage, Radhakrishnan Ramchandren, Nancy L Bartlett, Bruce D Cheson, Sven de Vos1, Andres Forero-Torres, Craig H Moskowitz, Joseph M Connors, Andreas Engert, Emily K Larsen, Dana A Kennedy, Eric L Sievers, and Robert Chen. Journal of Clinical Oncology. In press 2011
Advances in the Treatment of Relapsed or Refractory Hodgkins Lymphoma. The oncologist in press 2011 Author: R. Ramchandren.
Cryptococcus Albidus Infection in a Patient Undergoing Autologous Progenitor Cell Transplant. Transplantation. 2004;77(6):956 Authors: Ramchandren R, Gladstone D.
Dasatinib treatment of imatinib resistant CML. Biologics Target and Therapy. Biologics. 2009;3:205-14. Authors: Ramchandren R, Schiffer CA.
